No differences were found in the proportions of patients showing CAS improvement at 24 weeks ( 25 % placebo ; 31 % RTX , P = .75 ) or in CAS decrease from baseline to 24 or 52 weeks [ mean 1.5 points ( 1.8 SD ) placebo ; 1.2 ( 2 SD ) RTX at 24 weeks , P = .73 ] .